Abstract: Slide Presentations |

Quality of Life in Sarcoidosis Regarding the Treatment-Sarcoidosis Health Questionnaire FREE TO VIEW

Vladimir Zugic, MD; Branislav Gvozdenovic, MD; Jelica Videnovic, MD, PhD; Jasmina Maric-Zivkovic, MD; Snezana Filipovic, MD; Violeta Vucinic, MD, PhD*
Author and Funding Information

Institute of Pulmonary Diseases, Belgrade, Serbia


Chest. 2004;126(4_MeetingAbstracts):743S-c-744S. doi:10.1378/chest.126.4_MeetingAbstracts.743S-c
Text Size: A A A
Published online


PURPOSE:  Quality of life (QoL) researches in sarcoidosis have hardly received an appropriate attention. The most important explanation is the lack of disease-specific QoL questionnaire. Since May 2003 Sarcoidosis Health Questionnaire (SHQ) has been introduced. This is the first disease-specific questionnaire. The purpose of this study was to evaluate the QoL in sarcoidosis patients, regarding the treatment using SHQ .

METHODS:  197 biopsy positive sarcoidosis patients were analyzed. Considering the treatment patients were divided into three groups: I- 42 patients without therapy, II-115 patients treated with morbostatic doses of prednisolone (5-15mg/daily), III-40 patients treated with methotrexate (10-15 mg orally / weekly). The groups were similar regarding male/female ratio (1:2.5) and the mean age. Patients with comorbidity were excluded. SHQ scores were calculated by PC software, with author’s permission.

RESULTS:  Mean SHQ scores were the lowest in- the III group (daily 4.08±0.60, physical 4.13±0.89, emotional 3.92±0.63, total 4.04±0.5). All SHQ scores showed statistically significant differences between groups (p<0.01, ANOVA). Statistically significant correlation between all SHQ scores and therapy groups (p<0.01, Spearman’s rho coefficient) was found as well.

CONCLUSION:  The lowest SHQ scores were recorded in sarcoidosis patients with the chronic form, requiring cytotoxic treatment. SHQ is reliable instrument in evaluating health problems in broad spectrum of sarcoidosis patients: from those with modest disease requiring no treatment at all, to those with the most serious form of disease requiring cytotoxic treatment.

CLINICAL IMPLICATIONS:  SHQ is an excellent instrument for assessment of QoL in sarcoidosis patients that is highly recommended for routine clinical practice.

DISCLOSURE:  V. Vucinic, None.

Tuesday, October 26, 2004

10:30 AM- 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543